ID 180552 8 3 83 266276 RESEARCH Tumorinduced osteomalacia experience tertiary care centers India Rimesh Pal1 Sanjay Kumar Bhadada1 Awesh Singhare2 Anil Bhansali1 Sadishkumar Kamalanathan3 Manoj Chadha2 Phulrenu Chauhan2 Ashwani Sood4 Vandana Dhiman1 Dinesh Chandra Sharma5 Uma Nahar Saikia6 Debajyoti Chatterjee6 Vikas Agashe7 1Department Endocrinology Post Graduate Institute Medical Education Research Chandigarh India 2Department Endocrinology P D Hinduja Hospital Medical Research Centre Mumbai India 3Department Endocrinology Jawaharlal Institute Post Graduate Medical Education Research Pondicherry India 4Department Nuclear Medicine Post Graduate Institute Medical Education Research Chandigarh India 5Division Endocrinology Rabindranath Tagore Medical College Udaipur India 6Department Histopathology Post Graduate Institute Medical Education Research Chandigarh India 7Department Orthopaedics P D Hinduja Hospital Medical Research Centre Mumbai India Correspondence addressed S K Bhadada bhadadaskrediffmailcom Abstract Tumorinduced osteomalacia TIO rare paraneoplastic syndrome characterized recalcitrant hypophosphatemia Reports Indian subcontinent scarce single center experiences involving patients Herein conducted retrospective analysis 30 patients TIO diagnosed tertiary care hospitals India Patients persistent hypophosphatemia despite correction hypovitaminosis D normocalcemia elevated alkaline phosphatase low TmPGFR elevated inappropriately normal FGF23 levels labeled having TIO They sequentially subjected functional followed anatomical imaging Patients welllocalized tumor underwent excision phosphorous calcitriol supplementation The mean age presentation 396 years femalemale ratio 32 Bone pain 833 proximal myopathy 70 chief complaints 40 cases fractures The mean delay diagnosis 38 years Tumors clinically detectable patients 133 The mean serum phosphate 050 mmolL median serum FGF23 level 518 RUmL Somatostatin receptorbased scintigraphy superior FDGPET tumor localization Lower extremities common site tumor 72 Tumor size positively correlated serum FGF23 levels Twentytwo patients underwent tumor resection 16 phosphaturic mesenchymal tumors Surgical excision led cure 727 patients disease persistence disease recurrence seen 182 91 cases respectively At followup serum phosphate surgically treated group significantly higher medically managed group Key Words f tumorinduced osteomalacia f FGF23 f hypophosphatemia f phosphaturic mesenchymal tumor Endocrine Connections 2019 8 266276 Introduction Tumorinduced osteomalacia TIO known oncogenic osteomalacia rare paraneoplastic syndrome characterized persistent hypophosphatemia The basic pathophysiology underlying hypophosphatemia increased renal phosphate wasting consequent raised levels circulating phosphatonins The bestcharacterized phosphatonin fibroblast growth factor 23 FGF23 32 kDa polypeptide consisting 251 amino acids 1 In addition phosphatonins like secreted frizzled protein4 matrix extracellular phosphoglycoprotein httpsecbioscientificacom httpsdoiorg101530EC180552 2018 The authors This work licensed Creative Commons AttributionNonCommercialNoDerivatives 40 International License 180552 R Pal et alTumorinduced osteomalacia Indian experiencePublished Bioscientifica Ltd MEPE FGF 7 certain noncollagenous matrix proteins called SIBLING implicated 2 3 4 5 6 7 In cases small benign mesenchymal soft tissue tumors responsible increased FGF23 production 8 9 Besides causing phosphaturia FGF23 inhibits renal 1αhydroxylase enzyme converts 25hydroxy vitamin D active form 125dihydroxy vitamin D 10 Low levels active vitamin D impairs intestinal absorption phosphate deters mineralization osteoid matrix Chronic hypophosphatemia leads skeletal manifestations osteomalacia adults rickets children 11 Adults complain bone pains fatigue proximal myopathy fragility fractures 12 Untreated TIO leads significant morbidity debilitating 13 Fortunately complete tumoral excision leads rapid normalization biochemical parameters resolution symptoms 14 Around 300 cases TIO reported worldwide reports Indian subcontinent limited 2 15 16 17 18 19 20 21 Herein clinical features biochemical parameters imaging modalities treatment outcome 30 patients TIO diagnosed tertiary care hospitals India Materials methods A retrospective analysis medical records TIO cases diagnosed tertiary care hospitals January 2011 December 2017 conducted All patients 18 years age presented symptoms suggestive osteomalacia bone pain proximal muscle weakness andor fragility fractures underwent detailed historical evaluation special emphasis duration symptoms similar family history All patients similar family history excluded likely hereditary causes hypophosphatemic osteomalacia TIO A thorough physical examination concentrating lumps bumps present body performed patients samples investigations collected 8 h overnight fasting Serum calcium RR 215255 mmolL inorganic phosphate RR 087145 mmolL albumin RR 493696 μmolL RR 40129 IUL creatinine RR 353610606 μmolL measured autoanalyzer Roche Diagnostics Modular P 800 Calcium values corrected respective serum albumin levels Serum iPTH RR 1669 pmolL alkaline phosphatase biochemical reference Blood range 83 267 25OHD RR 271107 nmolL measured electrochemiluminescence assay commercially available kits Elecsys 2010 Roche Diagnostic Those having hypovitaminosis D time presentation parenterally supplemented 6 lakhs IU cholecalciferol biochemical panel repeated 4 weeks Patients remained symptomatic continued hypophosphatemia correction serum vitamin D levels suspected having hypophosphatemic osteomalacia In subsequently TmPGFR calculated help standard nomogram 22 Finally patients having refractory hypophosphatemia normocalcemia elevated ALP low TmPGFR underwent estimation serum FGF23 levels twosite enzymelinked immunosorbent assay Human FGF23 CTerm ELISA Quidel Immutopics RR 0150 RUmL coefficient variation 10 Patients biochemical profile elevated inappropriately normal FGF23 levels labeled having TIO Written informed consent publication clinical details andor clinical images obtained patients Ethical clearance study obtained Institutional Ethical Committee Post Graduate Institute Medical Education Research Chandigarh India scintigraphy Biochemical confirmation followed imaging studies attempt localize culprit tumor Functional imaging carried cases somatostatin receptorbased scintigraphy 68GaDOTATATEDOTANOC 99mTcHYNICTOC 18FFDG PETCT scan patients Anatomical tumor localization contrastenhanced computed tomography CT magneticresonance imaging MRI depending nature suspected lesion CT preferred bony lesions MRI preferred soft tissue lesions A thorough skeletal survey performed patients including radiographs skull cervical thoracic lumbosacral spine anteroposteriorlateral bilateral shoulders proximal humeri bones forearm hands rib cage pelvis proximal femur bones leg Patients welllocalized tumor underwent excision postsurgery serum phosphate level monitored daily till got normalized Serum FGF23 level repeated 2 months tumor resection Patients tumor localization surgically inaccessible tumors medically managed oral phosphate calcitriol supplementation Phosphate supplemented form sodium phosphate granules starting dose 20 mgkgday divided doses httpsecbioscientificacom httpsdoiorg101530EC180552 2019 The authors This work licensed Creative Commons AttributionNonCommercialNoDerivatives 40 International License R Pal et alTumorinduced osteomalacia Indian experiencePublished Bioscientifica Ltd PB11 83 268 gradually hiked dose 50 mgkgday attempt achieve serum phosphate low normal range Calcitriol supplemented starting dose 20 ngkgday divided doses titrated based serum iPTH urinary calcium levels A baseline ultrasonography kidneys medically treated patients rule nephrolithiasis nephrocalcinosis repeated half yearly Surgically treated patients presenting recurrence persistence symptoms underwent repeat imaging attempt localize residual recurrent lesion Subsequently reoperated medical management Serum phosphate levels followup compared surgically treated medically managed groups Statistical analysis carried Statistical Package Social Sciences SPSS 230 software program SPSS Inc ShapiroWilk test check normality data Normally distributed variables expressed mean sd Correlations serum phosphorous FGF23 tumor size SUVmax calculated Spearman correlation Students ttest independent samples compare serum phosphate levels initial presentation followup pre postoperative serum FGF23 levels Results Over period 7 years 2011 2017 total 30 cases TIO diagnosed tertiary care hospitals India The demographic data biochemical investigations 30 TIO patients summarized Table 1 The chief presenting complaints bone pain 833 followed proximal muscle weakness 70 Pathological fractures seen 12 patients 40 common site neck femur vertebral fractures The mean age patients fractures comparable 400 vs 404 years Physical examination locate culprit tumors 133 patients Table 2 Three visible naked eye patient 8 right leg knee patient 11 patient 17 lateral aspect left leg Fig 1 Patient 9 40yearold female palpable firm globular mass right gluteal region picked dedicated physical examination Functional localization lesion undertaken patient patient 17 visible lump lateral aspect left leg 68GaDOTATATEDOTANOC scintigraphy contrastenhanced computerized tomography performed Table 3 Wholebody somatostatin receptor SSTRbased scintigraphy performed patients 20 patients 99mTcHYNICTOC scan patients Fig 2 18FFDGPET performed patients SSTRbased scintigraphy FDGPET patient failed localize traceravid lesion Subsequently definite anatomical lesion localized 25 patients 833 The common site tumor localization lower extremity 72 followed nasal cavity paranasal sinuses 16 One patient subcutaneous lesion patients lesion localized mandible patients 2 28 Most lesions soft tissue tumors 60 rest 40 seen arise bones There statistically significant positive correlation tumor size FGF23 levels significant correlation SUVmax maximum standardized uptake volume obtained SSTRbased scintigraphy serum FGF23 levels Out 25 patients definite tumor localized 22 subsequently underwent surgery patients 1 22 The common histopathology phosphaturic mesenchymal tumor 16 patients 727 Fig 3 followed hemangiopericytoma 3 patients 136 Two patients giant cell tumors patients 3 14 arteriovenous left nasal cavity patient 4 hemangioma Postoperatively serum phosphorous normalized 18 patients 91 local recurrence required reoperation patients 12 16 Serum phosphorous normalize patients 182 Table 1 Summary demographic data biochemical investigations 30 TIO patients Parameter Value Mean age range FemaleMale Mean delay diagnosis range 396 119 1967 years 32 38 0515 years Mean serum phosphate 050 013 023078 mmolL range Mean TmP GFR range Mean corrected serum 036 016 007074 mmolL 224 018 mmolL calcium Median serum ALP IQR Median serum iPTH IQR Median serum 25OHD IQR 230 177404 IUL 676 5371027 pmolL 754 521129 nmolL Median serum FGF23 518 1026235 RUmL IQR httpsecbioscientificacom httpsdoiorg101530EC180552 2019 The authors This work licensed Creative Commons AttributionNonCommercialNoDerivatives 40 International License R Pal et alTumorinduced osteomalacia Indian experiencePublished Bioscientifica Ltd 83 269 persistent disease patients 2 3 14 19 They subsequently oral phosphorous calcitriol supplementation Postoperative serum FGF23 levels available 17 patients statistically significant decline FGF23 levels compared baseline P 0002 Patient 2 persistent disease postoperative FGF23 levels showed rise 307 vs 201 RUmL baseline In patient persistent disease patient 14 FGF23 remained high 1216 vs 3990 RUmL baseline Surgery patients tumor localization patients 23 25 26 28 29 surgically inaccessible tumor patient 27 patients willing surgery patients 24 30 They medical management Baseline mean serum phosphate medically surgically managed groups similar 045 vs 055 mmolL Figure 1 Clinical photographs patient 8 showing small lump medial aspect right knee A marked black arrow patient 17 showing large lobulated lump lateral aspect upper left leg B P 0217 At followup mean serum phosphorous surgically treated group higher medically treated group 100 vs 080 mmolL P 0006 Discussion We presented retrospective series 30 cases TIO diagnosed tertiary care institute country period 7 years Our patients relatively younger age presentation Bone pain proximal myopathy principal presenting complaints fractures seen 40 patients The detailed physical examination rewarding patients detecting primary lesion SSTR based scintigraphy proved superior conventional httpsecbioscientificacom httpsdoiorg101530EC180552 2019 The authors Figure 2 Fused 68GaDOTATATE PETCT images showing focal traceravid lesions right A patient 11 left nasal cavity B patient 10 right gluteal region C patient 9 medial aspect leg right knee D patient 8 This work licensed Creative Commons AttributionNonCommercialNoDerivatives 40 International License R Pal et alTumorinduced osteomalacia Indian experiencePublished Bioscientifica Ltd PB11 83 270 Table 2 Demographic data biochemical investigations individual TIO patients n 30 Patient Agesex Phosphate mmolL Corrected calcium mmolL ALP IUL iPTH pmolL 25OH D nmolL TmP GFR mmolL FGF23 RU mL Phosphate followup mmolL 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 55M 28M 26F 52F 34F 51M 36F 44F 40F 58M 53F 56F 41F 30M 49M 36F 43F 37M 67M 29F 42M 25M 38F 28M 52F 28F 19M 31F 35F 26F 055 042 023 058 065 052 048 048 042 039 023 078 045 071 055 065 029 039 045 042 055 042 045 058 048 074 071 058 048 039 228 215 205 230 228 250 223 230 218 218 235 230 203 218 220 208 235 223 235 203 220 223 250 235 213 233 230 225 228 230 395 314 343 351 240 178 324 476 149 160 180 490 212 173 141 467 189 160 433 528 475 488 220 324 340 139 212 188 160 178 604 748 2895 563 452 642 317 735 445 1019 829 473 3160 637 1368 651 1188 1053 565 603 531 200 540 965 848 444 1802 701 941 1351 599 174 649 272 174 135 749 569 389 819 113 399 160 115 187 849 152 123 744 671 532 489 759 444 102 127 484 539 427 174 007 019 019 019 017 025 023 042 034 018 020 046 052 065 029 039 045 055 074 040 050 040 029 053 011 061 036 046 036 036 288 201 918 814 148 264 1239 349 523 513 1936 550 1771 3990 2581 2407 4298 6435 244 102 257 2620 1110 193 258 669 341 451 197 1628 103 068 071 110 136 120 120 123 155 149 113 065 100 032 113 097 090 103 065 087 103 090 078 071 078 087 074 084 094 081 FDGPET localizing culprit tumors Soft tissue tumors commonly encountered bony tumors thighs predominant site The common histological tumor subtype phosphaturic mesenchymal type tumormixed connective Surgical excision led cure 727 patients disease persistence disease recurrence seen 182 91 cases respectively tissue The mean age patients time initial presentation 396 years half decade earlier reported world literature 23 24 25 It congruence earlier report India 15 possibly implying TIO tends present somewhat earlier population There femalemale ratio 32 Usually TIO shows gender predilection tends affect males females equally 24 26 27 female dominance series merely reflect referral bias However occasional case series depicting female preponderance reported past 28 29 Most patients complained bone pain proximal muscle weakness However 40 patients radiologically proven pathological fractures This appears fairly low compared world literature reported fracture rates high 84100 23 24 The mean delay presentation 38 years similar earlier reports 23 30 Thirteen percent tumors clinically identifiable palpable visible lumps highlighting importance thorough headtotoe examination Biochemical investigations revealed hypophosphatemia normocalcemia patients Hypophosphatemia severe 60 patients having serum phosphate levels 050 nmolL Only 433 cases vitamin D deficient insufficient opposed 70100 general population Indian subcontinent 31 This patients supplemented vitamin D empirical treatment primary care hospitals The calculated TmPGFR low compared age sexspecific reference range patients implying renal phosphate wasting Serum FGF23 levels elevated upper limit httpsecbioscientificacom httpsdoiorg101530EC180552 2019 The authors This work licensed Creative Commons AttributionNonCommercialNoDerivatives 40 International License R Pal et alTumorinduced osteomalacia Indian experiencePublished Bioscientifica Ltd 83 271 Figure 3 Photomicrograph phosphaturic mesenchymal tumormixed connective tissue type A Photomicrograph showing relatively circumscribed focally tissue permeating mass hematoxylin eosin 20 B C Myoid spindle cell component hemangiopericytomatous blood vessels scattered osteoclastic giant cells siderophages hematoxylin eosin 100 4b 200 4c D Other areas showing areas grungy calcification spindle cell component hematoxylin eosin 40 assay range patients patients 5 20 These patients serum FGF23 levels 102 147 RUmL corresponding serum phosphate 042 065 nmolL respectively implying inappropriately normal FGF23 degree hypophosphatemia 30 32 Moreover estimation FGF23 patients Cterminal assay sensitivity reach 100 33 34 Other phosphatonins implicated causing phosphaturia patients 4 5 6 7 35 We statistically significant correlation serum phosphate FGF23 levels rs 022 P 024 probably serum phosphate correlates FGF23 measured intact assay Cterminal assay 36 Functional imaging SSTRbased scintigraphy FDGPET localize traceravid lesion 28 29 patients However subsequent attempt anatomical localization pinpoint culprit lesion 25 patients The concordance rate SSTRbased scintigraphy anatomical imaging defined ability imaging modalities localize common lesion 100 concordance FDGPET anatomical imaging 50 The superiority SSTRbased scintigraphy FDGPET localizing culprit lesions TIO documented world literature 37 38 39 Most localized lesions soft tissue origin 60 Forty percent tumors seen arise bones similar reported case series 24 28 Although recent literature supports clear anatomical predilection tumors 11 striking lower limb predominance 72 thighs common site Two patients multifocal benign tumors patients 19 21 rarely reported 16 21 40 41 One patient 21 42yearold male 16 FDGavid nodule right leg measuring 09 06 10 cm synchronous nonFDGavid nodule left thigh picked MRI measuring 08 07 cm Excision FDGavid nodule lead resolution hypophosphatemia However nonFDGavid lesion removed hypophosphatemia settled serum FGF23 came 22 RUmL Data tumor size noted CTMRI 17 patients Tumor size serum available phosphate negatively correlated statistically significant rs 013 P 061 contrary statistically significant positive correlation tumor size serum FGF23 levels rs 057 P 0016 highlighting fact tumor size probably dictates FGF23 levels Data maximum standardized uptake volume SUVmax 68Galabeled peptide scintigraphy available 15 patients No statistically significant correlation SUVmax serum FGF23 levels rs 017 P 051 Since SUVmax surrogate marker SSTR expression 42 inferred signal transduction somatostatin receptors possibly involved regulation FGF23 secretion tumor tissue As firm evidence hypothesis httpsecbioscientificacom httpsdoiorg101530EC180552 2019 The authors This work licensed Creative Commons AttributionNonCommercialNoDerivatives 40 International License R Pal et alTumorinduced osteomalacia Indian experiencePublished Bioscientifica Ltd 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 PB11 83 272 Table 3 Various functional anatomical imaging modalities tumor localization histopathology tumors excised Patient Functional imaging Site localized functional imaging Anatomical imaging 68GaDOTATATE 68GaDOTATATE 68GaDOTATATE 68GaDOTATATE 68GaDOTATATE 68GaDOTATATE 68GaDOTATATE 68GaDOTATATE 68GaDOTATATE 68GaDOTATATE 68GaDOTATATE 68GaDOTATATE 68GaDOTANOC FDGPET 68GaDOTANOC FDGPET NOT DONE Right thigh Mandible Head left fibula Right nasal cavity Right thigh Shaft right femur Right maxillary sinus Right leg Right gluteal region Left nasal cavity Right Right pelvic blade Right thigh Left thigh Right acetabulum Left nasal cavity NA CEMRI CECT CECT CECT CEMRI CECT CECT CECT CEMRI CECT CECT CEMRI CECT CECT CEMRI CECT CECT 68GaDOTANOC 99mTcHYNICTOC Right heel Right medial femoral CEMRI CECT condyle S2 vertebral body 99mTcHYNICTOC FDGPET Left thigh Right thigh Site localized anatomical imaging Concordant Concordant Concordant Concordant Concordant Concordant Concordant Concordant Concordant Concordant Concordant Concordant Concordant Concordant Concordant Concordant Left proximal fibula Concordant Concordant Tissue origin Soft tissue Bone Bone Soft tissue Soft tissue Bone Soft tissue Soft tissue Soft tissue Soft tissue Soft tissue Bone Soft tissue Soft tissue Bone Soft tissue Bone Histopathology PMTMCT HPT GCT AV hemangioma PMTMCT PMTMCT PMTMCT PMTMCT PMTMCT HPTsinonasal type PMTMCT PMTMCT PMTMCT GCT PMTMCT HPTlipomatous type PMTMCT Soft tissue Bone PMTMCT PMT osteoblastomalike variant CEMRI CECT CEMRI Concordant Left thigh Soft tissue Soft tissue PMTMCT PMTMCT FDGPET Right proximal fibular CECT Concordant Bone PMTMCT FDGPET 68GaDOTATATE 68GaDOTATATE 68GaDOTATATE FDGPET 68GaDOTATATE 68GaDOTATATE FDGPET 68GaDOTATATE shaft Left ala sacrum Head left femur Right patella Not localized CEMRI CEMRI CECT NOT DONE Not localized Concordant Not localized NA NA Bone NA NA NA NA NA NA Right obturator CEMRI Concordant Soft tissue NA muscle Mandible C4 vertebra Midleft fibula CECT CECT CECT Not localized Not localized Concordant NA NA Bone NA NA NA NA applicable fact octreotide somatostatin receptor ligand largely ineffective correcting biochemical abnormalities TIO 43 44 45 All resected tumors n 22 benign nature Sixteen 727 phosphaturic mesenchymal tumors PMT mixed connective tissue variant PMTMCT commonly seen 15 patients osteoblastomalike variant Three patients 136 hemangiopericytomas giant cell tumors GCTs harbored arteriovenous hemangioma The present data consistent world literature showing predominance PMTMCT cases 23 24 Although surgery remains mainstay therapy treatment modalities tried varying degrees success Imageguided ablation different techniques including percutaneousethanol ablation radiofrequency ablation cryoablation offers minimally invasive safe treatment option patients inoperable TIO However efficacy varies longterm effects known 46 47 48 Radiotherapy adjuvant primary treatment modality remains viable option unresectable incompletely resected tumors 49 50 Deliberate total parathyroidectomy novel treatment approach advocated refractory cases 2 httpsecbioscientificacom httpsdoiorg101530EC180552 2019 The authors This work licensed Creative Commons AttributionNonCommercialNoDerivatives 40 International License R Pal et alTumorinduced osteomalacia Indian experiencePublished Bioscientifica Ltd Cinacalcet octreotide tried variable success 51 52 In addition antiFGF23 antibody known KRN23 Burosumab evaluated treatment TIO 53 Postoperatively serum phosphorous normalized 18 22 patients period 3 days 2 months Two patients 91 local recurrence 6 months reoperated A local recurrence rate 5 reported world literature 54 patients harboring malignant tumor operating surgeon able resect tumor en bloc likely reason patients In patients 182 serum phosphorous got normalized believed persistent disease Disease persistence following surgical excision documented literature 55 Repeat SSTRbased scintigraphy patients revealed new traceravid lesion right femur patient right foot patient However CEMRI inconclusive The patients local residues unwilling repeat surgery Postoperative FGF23 levels showed statistically significant decline compared preoperative values Fig 4 However contrary expectations FGF23 levels fall upper limit reference range assay 0150 RUmL patients unequivocal evidence clinical biochemical cure This highlights fact percentage decline FGF23 surgery absolute value correlates disease cure The mean percentage decline FGF23 associated clinical biochemical cure 811 range 275992 Serum phosphate surgically treated group significantly higher followup compared medically managed group P 0006 Fig 5 However medically managed group serum phosphate level followup significantly higher compared baseline values P 0001 Thus phosphate calcitriol supplementation TIO patients tumor localized improve biochemical milieu translates improved quality life debatable The principal strength study relatively large sample size Prior case series India single center experiences included patients 15 On contrary multicenter study involving 30 patients cases recruited tertiary care hospitals catering northern western southern parts nation In addition somatostatin receptorbased scintigraphy 83 273 patients best imaging modality published literature Moreover attempt correlate tumor characteristics serum FGF23 levels bear therapeutic implications best knowledge reported earlier The primary limitation study fact patients underwent surgery patients tumor anatomically localized unwilling surgery medical management Hence data tumor histology available patients Lastly measured serum FGF23 levels Cterminal ELISA technique measures intact FGF23 Cterminal fragments FGF23 Traditionally believed intact FGF23 biologically active molecule mediating phosphaturia 56 Hence estimation intact Cterminal fragments FGF23 theoretically overestimate actual bioactivity circulating molecule Figure 4 Box whisker plot showing preoperative postoperative serum FGF23 levels 17 surgically treated TIO patients P 0002 httpsecbioscientificacom httpsdoiorg101530EC180552 2019 The authors This work licensed Creative Commons AttributionNonCommercialNoDerivatives 40 International License R Pal et alTumorinduced osteomalacia Indian experiencePublished Bioscientifica Ltd PB11 83 274 Author contribution statement R P S K B helped study design The study conducted R P S K B A B Data collection V D A S S K M C P C D C S V A A S D provided scintigraphy data U N S D C provided histopathology data Data analysis R P V D Data interpretation S K B R P A B R P S K B S K A S D M C helped drafting manuscript S K B S K A S D A S revised manuscript content R P S K B A B A S M C P C S K S K B approved final version manuscript responsibility integrity data analysis References 1 Liu S Quarles LD How fibroblast growth factor 23 works Journal American Society Nephrology 2007 18 16371647 httpsdoi org101681ASN2007010068 2 Bhadada SK Palnitkar S Qiu S Parikh N Talpos GB Rao SD Deliberate total parathyroidectomy A potentially novel therapy tumorinduced hypophosphatemic osteomalacia Journal Clinical Endocrinology Metabolism 2013 98 42734278 httpsdoi org101210jc20132705 3 Carpenter TO Ellis BK Insogna KL Philbrick WM Sterpka J Shimkets R Fibroblast growth factor 7 inhibitor phosphate transport derived oncogenic osteomalaciacausing tumors Journal Clinical Endocrinology Metabolism 2005 90 10121020 httpsdoiorg101210jc20040357 4 Rowe PS Kumagai Y Gutierrez G Garrett IR Blacher R Rosen D Cundy J Navvab S Chen D Drezner MK et al MEPE properties osteoblastic phosphatonin minhibin Bone 2004 34 303319 httpsdoiorg101016jbone200310005 5 Schiavi SC Moe OW Phosphatonins new class phosphate regulating proteins Current Opinion Nephrology Hypertension 2002 11 423430 httpsdoiorg10109700041552200207000 00009 6 Shaikh A Berndt T Kumar R Regulation phosphate homeostasis phosphatonins novel mediators Pediatric Nephrology 2008 23 12031210 httpsdoiorg101007s00467008 0751z 7 Berndt T Craig TA Bowe AE Vassiliadis J Reczek D Finnegan R Jan De Beur SM Schiavi SC Kumar R Secreted frizzledrelated protein 4 potent tumorderived phosphaturic agent Journal Clinical Investigation 2003 112 785794 httpsdoiorg101172 JCI18563 8 Alonso G Varsavsky M Tumourinduced osteomalacia emergent paraneoplastic syndrome Endocrinologia y Nutricion 2016 63 181186 httpsdoiorg101016jendonu201510011 9 Weidner N Review update oncogenic osteomalacia rickets Ultrastructural Pathology 1991 15 317333 httpsdoi org10310901913129109016242 10 Perwad F Portale AA Vitamin D metabolism kidney regulation phosphorus fibroblast growth factor 23 Molecular Cellular Endocrinology 2011 347 1724 httpsdoi org101016jmce201108030 11 Minisola S Peacock M Fukumoto S Cipriani C Pepe J Tella SH Collins MT Tumourinduced osteomalacia Nature Reviews Disease Primers 2017 3 17044 httpsdoiorg101038nrdp201744 12 Chong WH Molinolo AA Chen CC Collins MT Tumorinduced Figure 5 Bar diagram showing serum phosphate levels surgically n 22 medically n 8 treated TIO patients measured presentation P 0217 followup P 0006 However animal studies shown carboxyl terminal fragments FGF23 phosphaturic 57 hold true humans fact estimation FGF23 Cterminal ELISA correlate better bioactivity In conclusion TIO kept differential diagnosis evaluating patient osteomalacia Persistent hypophosphatemia despite normalization vitamin D status absence similar family history strengthens possibility TIO A thorough physical examination rewarding obviate need imaging Serum FGF23 levels inappropriately normal degree hypophosphatemia Somatostatin receptorbased scintigraphy preferred imaging modality localize tumor Surgical resection offers definitive cure recurrences occur long term followup necessary Declaration The authors declare conflict perceived prejudicing impartiality research reported osteomalacia EndocrineRelated Cancer 2011 18 R53R77 httpsdoi org101530ERC110006 13 Tarasova VD TreppCarrasco AG Thompson R Recker RR Funding This research receive specific grant funding agency public commercial notforprofit sector Chong WH Collins MT Armas LAG Successful treatment tumorinduced osteomalacia intracranial tumor fractionated stereotactic radiotherapy Journal Clinical Endocrinology Metabolism 2013 98 42674272 httpsdoiorg101210 jc20132528 httpsecbioscientificacom httpsdoiorg101530EC180552 2019 The authors This work licensed Creative Commons AttributionNonCommercialNoDerivatives 40 International License R Pal et alTumorinduced osteomalacia Indian experiencePublished Bioscientifica Ltd 83 275 14 Sun ZJ Jin J Qiu GX Gao P Liu Y Surgical treatment tumor induced osteomalacia retrospective review 40 cases extremity tumors BMC Musculoskeletal Disorders 2015 16 43 https doiorg101186s1289101504963 15 Jagtap VS Sarathi V Lila AR Malhotra G Sankhe SS Bandgar T Menon P Shah NS Tumorinduced osteomalacia single center experience Endocrine Practice 2011 17 177184 httpsdoi org104158EP10151OR 16 Sahoo J Balachandran K Kamalanathan S Das AK Patro DK Halanaik D Badhe B Tumors induced osteomalaciaa curious case double trouble Journal Clinical Endocrinology Metabolism 2014 99 395398 httpsdoiorg101210jc20133791 17 Bhatt AA Mathews SS Kumari A Paul TV Tumourinduced osteomalacia Hong Kong Medical Journal 2014 20 350e1350e2 httpsdoiorg1012809hkmj133981 18 Ashish G Mathew J Thomas N Kapoor N Elanthenral S Phosphaturic mesenchymal tumour temporal bone rare presentation Egyptian Journal Ear Nose Throat Allied Sciences 2014 15 149153 httpsdoiorg101016jejenta201312008 19 Verma A Tewari S Kannaujia A Perioperative management patients severe hypophosphataemia secondary oncogenic osteomalacia experience review literature Indian Journal Anaesthesia 2017 61 590593 httpsdoiorg104103ija IJA_57_17 20 Dutta D Pandey RK Gogoi R Solanki N Madan R Mondal A Dogra S Thapa P Occult phosphaturic mesenchymal tumor femur cortex causing oncogenic osteomalacia diagnostic challenges clinical outcomes Endokrynologia Polska 2018 69 205210 httpsdoiorg105603EPa20180016 21 Annamalai AK Sampathkumar K Kane S Shetty NS Kulkarni S Rangarajan V Purandare N Pai PS Mahuvakar AD Shanthi R et al Needles haystacksynchronous multifocal tumorinduced osteomalacia Journal Clinical Endocrinology Metabolism 2016 101 390393 httpsdoiorg101210jc20153854 22 Walton RJ Bijvoet OLM Nomogram derivation renal threshold phosphate concentration Lancet 1975 2 309310 https doiorg101016S0140673675927361 23 Yu WJ He JW Fu WZ Wang C Zhang ZL Reports 17 Chinese patients tumorinduced osteomalacia Journal Bone Mineral Metabolism 2017 35 298307 httpsdoiorg101007 s0077401607569 review 53 cases head neck Head Neck Pathology 2016 10 192200 httpsdoiorg101007s1210501506683 30 Zuo QY Wang H Li W Niu XH Huang YH Chen J You YH Liu BY Cui AM Deng W Treatment outcomes tumorinduced osteomalacia associated phosphaturic mesenchymal tumors retrospective review 12 patients BMC Musculoskeletal Disorders 2017 18 403 httpsdoiorg101186s1289101717561 31 Ritu G Gupta A Vitamin D deficiency India prevalence causalities interventions Nutrients 2014 6 729775 httpsdoi org103390nu6020729 32 Amblee A Uy J Senseng C Hart P Tumorinduced osteomalacia normal systemic fibroblast growth factor23 level Clinical Kidney Journal 2014 7 186189 httpsdoiorg101093ckjsfu004 33 Smith ER McMahon LP Holt SG Fibroblast growth factor 23 Annals Clinical Biochemistry 2014 51 203227 httpsdoi org1011770004563213510708 34 Imel EA Peacock M Pitukcheewanont P Heller HJ Ward LM Shulman D Kassem M Rackoff P Zimering M Dalkin A et al Sensitivity fibroblast growth factor 23 measurements tumor induced osteomalacia Journal Clinical Endocrinology Metabolism 2006 91 20552061 httpsdoiorg101210jc20052105 35 Jonsson KB Zahradnik R Larsson T White KE Sugimoto T Imanishi Y Yamamoto T Hampson G Koshiyama H Ljunggren O et al Fibroblast growth factor 23 oncogenic osteomalacia Xlinked hypophosphatemia New England Journal Medicine 2003 348 16561663 httpsdoiorg101056NEJMoa020881 36 Burnett SAM Gunawardene SC Bringhurst FR Jüppner H Lee H Finkelstein JS Regulation Cterminal intact FGF 23 dietary phosphate men women Journal Bone Mineral Research 2006 21 11871196 httpsdoiorg101359jbmr060507 37 Agrawal K Bhadada S Mittal BR Shukla J Sood A Bhattacharya A Bhansali A Comparison 18FFDG 68Ga DOTATATE PET CT localization tumor causing oncogenic osteomalacia Clinical Nuclear Medicine 2015 40 e6e10 httpsdoiorg101097 RLU0000000000000460 38 Jadhav S Kasaliwal R Lele V Rangarajan V Chandra P Shah H Malhotra G Jagtap VS Budyal S Lila AR et al Functional imaging primary tumourinduced osteomalacia relative performance FDG PETCT vs somatostatin receptorbased functional scans series patients Clinical Endocrinology 2014 81 3137 httpsdoi org101111cen12426 24 Jiang Y Xia WB Xing XP Silva BC Li M Wang O Zhang HB Li F 39 ElMaouche D Sadowski SM Papadakis GZ Guthrie L Cottle Jing HL Zhong DR et al Tumorinduced osteomalacia important cause adultonset hypophosphatemic osteomalacia China report 39 cases review literature Journal Bone Mineral Research 2012 27 19671975 httpsdoiorg101002 jbmr1642 25 Dadoniene J Miglinas M Miltiniene D Vajauskas D Seinin D Butenas P Kacergius T Tumourinduced osteomalacia literature review case report World Journal Surgical Oncology 2016 14 4 httpsdoiorg101186s1295701507637 26 Ryan EA Reiss E Oncogenous osteomalacia Review world literature 42 cases report new cases American Journal Medicine 1984 77 501512 httpsdoiorg1010160002 934384901128 27 Florenzano P Gafni RI Collins MT Tumorinduced osteomalacia Bone Reports 2017 7 9097 httpsdoiorg101016j bonr201709002 28 Folpe AL FanburgSmith JC Billings SD Bisceglia M Bertoni F Cho JY Econs MJ Inwards CY Jan De Beur SM Mentzel T et al Most osteomalaciaassociated mesenchymal tumors single histopathologic entity analysis 32 cases comprehensive review literature American Journal Surgical Pathology 2004 28 130 httpsdoiorg1010970000047820040100000001 29 Qari H HamaoSakamoto A Fuselier C Cheng YS Kessler H Wright J Phosphaturic mesenchymal tumor 2 new oral cases Delisle C Merkel R Millo C Chen CC Kebebew E Collins MT GaDOTATATE tumor localization tumorinduced osteomalacia Journal Clinical Endocrinology Metabolism 2016 101 35753581 httpsdoiorg101210jc20162052 40 Arai R Onodera T Terkawi MA Mitsuhashi T Kondo E Iwasaki N A rare case multiple phosphaturic mesenchymal tumors tendon sheath inducing osteomalacia BMC Musculoskeletal Disorders 2017 18 79 httpsdoiorg101186s128910171446z 41 Higley M Beckett B Schmahmann S Dacey E Foss E Locally aggressive multifocal phosphaturic mesenchymal tumors unusual cases tumorinduced osteomalacia Skeletal Radiology 2015 44 18251831 httpsdoiorg101007s002560152246x 42 Campana D Ambrosini V Pezzilli R Fanti S Labate AMM Santini D Ceccarelli C Nori F Franchi R Corinaldesi R et al Standardized uptake values 68GaDOTANOC PET A promising prognostic tool neuroendocrine tumors Journal Nuclear Medicine 2010 51 353359 httpsdoiorg102967jnumed109066662 43 Paglia F Dionisi S Minisola S Octreotide tumorinduced osteomalacia New England Journal Medicine 2002 346 17481749 author reply 1748 httpsdoiorg101056 NEJM200205303462215 44 Ovejero D ElMaouche D Brillante BA Khosravi A Gafni RI Collins MT Octreotide ineffective treating tumorinduced osteomalacia results shortterm therapy octreotide ineffective httpsecbioscientificacom httpsdoiorg101530EC180552 2019 The authors This work licensed Creative Commons AttributionNonCommercialNoDerivatives 40 International License R Pal et alTumorinduced osteomalacia Indian experiencePublished Bioscientifica Ltd PB11 83 276 treating tio Journal Bone Mineral Research 2017 32 16671671 httpsdoiorg101002jbmr3162 45 Mékinian A Ladsous M Balavoine AS Carnaille B Aubert S Soudan B Wémeau JL Curative surgical treatment inefficient longacting somatostatin analogues therapy tumorinduced osteomalacia Presse Médicale 2011 40 309313 httpsdoi org101016jlpm201010011 46 Jadhav S Kasaliwal R Shetty NS Kulkarni S Rathod K Popat B Kakade H Bukan A Khare S Budyal S et al Radiofrequency ablation effective modality treatment tumorinduced osteomalacia case series patients Journal Clinical Endocrinology Metabolism 2014 99 30493054 httpsdoiorg101210jc2013 4515 47 Hesse E Rosenthal H Bastian L Radiofrequency ablation tumor causing oncogenic osteomalacia New England Journal Medicine 2007 357 422424 httpsdoiorg101056NEJMc070347 48 Tutton S Olson E King D Shaker JL Successful treatment tumorinduced osteomalacia CTguided percutaneous ethanol cryoablation Journal Clinical Endocrinology Metabolism 2012 97 34213425 httpsdoiorg101210jc20121719 49 Caudell JJ Ballo MT Zagars GK Lewis VO Weber KL Lin PP Marco RA ElNaggar AK Benjamin RS Yasko AW Radiotherapy management giant cell tumor bone International Journal Radiation Oncology Biology Physics 2003 57 158165 httpsdoi org101016S0360301603004164 50 Hautmann AH Hautmann MG Kölbl O Herr W Fleck M Tumor induced osteomalacia uptodate review Current Rheumatology Reports 2015 17 512 httpsdoiorg101007s1192601505125 51 Geller JL Khosravi A Kelly MH Riminucci M Adams JS Collins MT Cinacalcet management tumorinduced osteomalacia Journal Bone Mineral Research 2007 22 931937 httpsdoiorg101359jbmr070304 52 Seufert J Ebert K Müller J Eulert J Hendrich C Werner E Schütze N Schulz G Kenn W Richtmann H et al Octreotide therapy tumor induced osteomalacia New England Journal Medicine 2001 345 18831888 httpsdoiorg101056NEJMoa010839 53 Kinoshita Y Fukumoto S AntiFGF23 antibody therapy patients tumorinduced osteomalacia Clinical Calcium 2014 24 12171222 54 Yavropoulou MP Gerothanasi N Frydas A Triantafyllou E Poulios C Hytiroglou P Apostolou P Papasotiriou I Tournis S Kesisoglou I et al Tumorinduced osteomalacia recurrent mesenchymal tumor overexpressing growth factor receptors Endocrinology Diabetes Metabolism Case Reports 2015 2015 150025 httpsdoi org101530EDM150025 55 Chong WH Andreopoulou P Chen CC Reynolds J Guthrie L Kelly M Gafni RI Bhattacharyya N Boyce AM ElMaouche D et al Tumor localization biochemical response cure tumor induced osteomalacia Journal Bone Mineral Research 2013 28 13861398 httpsdoiorg101002jbmr1881 56 Shimada T Urakawa I Isakova T Yamazaki Y Epstein M Wesseling Perry K Wolf M Salusky IB Jüppner H Circulating fibroblast growth factor 23 patients endstage renal disease treated peritoneal dialysis intact biologically active Journal Clinical Endocrinology Metabolism 2010 95 578585 httpsdoi org101210jc20091603 57 Berndt TJ Craig TA McCormick DJ Lanske B Sitara D Razzaque MS Pragnell M Bowe AE OBrien SP Schiavi SC et al Biological activity FGF 23 fragments Pflugers Archiv 2007 454 615623 httpsdoi org101007s0042400702315 Received final form 24 January 2019 Accepted 28 January 2019 Accepted Preprint published online 6 February 2019 httpsecbioscientificacom httpsdoiorg101530EC180552 2019 The authors This work licensed Creative Commons AttributionNonCommercialNoDerivatives 40 International License R Pal et alTumorinduced osteomalacia Indian experiencePublished Bioscientifica Ltd